Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
NAD⁺ & NMN
Research brief

Resveratrol reduced age-related skin thinning in mice, with SIRT1-related cell findings

In mice, dietary resveratrol given from 28 to 60 weeks of age attenuated the age-related thinning of epidermis and dermis seen in untreated aged mice; the abstract also reports SIRT1-related cell changes and keratinocyte experiments. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Epidermal and dermal thickness were significantly reduced in 60-week-old mice compared with 20-week-old mice. [1]

  2. Dietary resveratrol at 0.4 g/kg diet from 28 weeks of age for 32 weeks attenuated these thickness changes. [1]

  3. SIRT1 knockdown in human HaCaT keratinocytes increased p21 expression and senescence-associated β-galactosidase activity. [1]

The source at a glance

Study type / format
Animal study with cell experiments (abstract)
Population / context
Mice aged 20 and 60 weeks, plus human HaCaT keratinocytes in cell experiments.
Summary based on
Study abstract
Original publication
August 24, 2026

Mice aged 20 versus 60 weeks, with resveratrol feeding

The study asked whether dietary resveratrol, described as a SIRT1 activator, mitigates age-related skin thinning in mice. Epidermal and dermal thickness were significantly reduced in 60-week-old mice compared with 20-week-old mice. Resveratrol was given at 0.4 g per kg of diet from 28 weeks of age for 32 weeks, and these thickness changes were attenuated. The abstract does not report group sizes or how many mice were compared.

Supporting source [1]

Epidermal cell counts and dermal markers in aged mice

In the epidermis, the number of Ki67-positive cells fell in aged mice but was restored by resveratrol. Resveratrol did not change the number of SIRT1-positive cells but significantly reduced acetyl-lysine-positive cells, which the authors read as enhanced SIRT1 activity. In the dermis, the areas positive for MMP-9 and MMP-13 rose with age, and these age-associated increases were not seen in resveratrol-treated aged mice. Phosphorylated SMAD2 levels fell with age but were not affected by resveratrol.

Supporting source [1]

Keratinocyte knockdown supports a proposed mechanism

In human HaCaT keratinocytes, knockdown of SIRT1 increased p21 expression and senescence-associated β-galactosidase activity. The authors conclude that resveratrol may ameliorate age-related skin thinning by suppressing cellular senescence in the epidermis and inhibiting dermal collagen degradation. These are proposed mechanisms from mouse and cell experiments, not demonstrated human skin benefits. The abstract does not report the full text, so details of design, statistics and safety were not reviewed.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. Findings come from mice and from HaCaT keratinocytes, and the abstract does not report group sizes, statistics or safety data. Proposed mechanisms are not demonstrated human skin benefits.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
SIRT1 Activator Resveratrol Attenuates Age-Related Skin Thinning in Mice.

Tamura F, Nojima I, Kunimoto R, Hosoda R, Kuwabara Y, Kawakami K, Horimoto K, Kuno A. · europepmc.org · August 24, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    significantly reduced in 60-week-old (wo) mice compared
  2. Finding 2 ↑

    attenuated by RSV administration (0.4 g/kg diet)
  3. Finding 3 ↑

    SIRT1 knockdown in human HaCaT keratinocytes increased

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…